Full Press Release Details
USANA Health Sciences Reports Second Quarter Net Sales of $238 Million and Diluted EPS of $0.89
SALT LAKE CITY--(BUSINESS WIRE)--July 25, 2023--USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal second quarter ended July 1, 2023.
Key Financial & Operating Results
Second quarter net sales were $238 million versus $264 million during the second quarter of 2022.
Second quarter diluted EPS was $0.89 as compared with $1.00 during the second quarter of 2022.
Fiscal 2023 net sales and diluted EPS guidance updated to $900 to $950 million and $2.65 to $3.30, respectively, from $875 million to $950 million and $2.40 to $3.30.
Q2 2023 Financial Performance
| Consolidated Results | ||
| Net Sales | $238 million | -10% vs. Q2 2022 -6% constant currency vs. Q2 2022 -$10 million YOY FX impact, or -4% -4% sequentially -2% constant currency sequentially |
| Diluted EPS | $0.89 | -11% vs. Q2 2022 -6% sequentially Diluted shares of 19.4 million |
| Active Customers | 487,000 | -13% vs. Q2 2022 -1% sequentially |
"USANA's second quarter results were modestly ahead of internal expectations, highlighted by sequential improvement in mainland China and continued progress on several key strategic initiatives," said Jim Brown, President and Chief Executive
"Net sales in the second quarter declined 4% sequentially when compared to the first quarter of 2023. Net sales in the first quarter benefitted from increased demand for several of our health products in China following the government's shift
in COVID policy. In addition, the announcement of product price increases in several markets stimulated purchasing ahead of those increases. Collectively, these two events contributed an estimated $25 million to top line results in the first
"Our leadership team continued to emphasize in-person engagement with our Associate leaders through live events and meetings across several of our key markets. Notably, during the second quarter, we held both our Asia Pacific Convention in
South Korea and our national sales meeting in China. Both of these events generated strong attendance and enthusiasm. At these events we also announced USANA's plans to open our 25th global market, India, where our team is diligently working to
commence operations in late 2023. Although we anticipate that it will take time to build our business in this new market, we are confident that India will contribute to the long-term growth of USANA over the coming years."
Q2 2023 Regional Results:
| Asia Pacific Region | ||
| Net Sales | $194 million | -11% vs. Q2 2022 -7% constant currency vs. Q2 2022 -3% sequentially -1% constant currency sequentially 81% of consolidated net sales |
| Active Customers | 384,000 | -12% vs. Q2 2022 -1% sequentially |
| Asia Pacific Sub-Regions | ||
| Greater China | ||
| Net Sales | $129 million | -9% vs. Q2 2022 -4% constant currency vs. Q2 2022 +4% sequentially +6% constant currency sequentially |
| Active Customers | 251,000 | -10% vs. Q2 2022 +4% sequentially |
| North Asia | ||
| Net Sales | $26 million | -11% vs. Q2 2022 -7% constant currency vs. Q2 2022 -14% sequentially -11% constant currency sequentially |
| Active Customers | 51,000 | -11% vs. Q2 2022 -6% sequentially |
| Southeast Asia Pacific | ||
| Net Sales | $39 million | -18% vs. Q2 2022 -14% constant currency vs. Q2 2022 -15% sequentially -13% constant currency sequentially |
| Active Customers | 82,000 | -20% vs. Q2 2022 -9% sequentially |
| Americas and Europe Region | ||
| Net Sales | $44 million | -5% vs. Q2 2022 -5% constant currency vs. Q2 2022 -8% sequentially -9% constant currency sequentially 19% of consolidated net sales |
| Active Customers | 103,000 | -15% vs. Q2 2022 -2% sequentially |
"Our strategic focus remains squarely on increasing the number of Active Customers. In addition to the emphasis on in-person meetings and events, our efforts include new market expansion, incentive opportunities for our salesforce, the ongoing
pursuit of accretive acquisition opportunities, and expanding our digital commerce capabilities," continued Mr. Brown. "We remain optimistic that the successful execution of our strategies will position USANA for a return to long-term growth."
Fiscal Year 2023 Outlook
The Company is raising the lower end of its net sales and earnings per share outlook for fiscal year 2023 as follows:
| Fiscal Year 2023 Outlook | ||
| Revised Range | Previous Range | |
| Consolidated Net Sales | $900 - $950 million | $875 - $950 million |
| Diluted EPS | $2.65 - $3.30 | $2.40 - $3.30 |
"A large global promotion was offered in the second quarter of 2022, which did not reoccur in 2023 and created a difficult year-over-year comparison for the current year quarter. Operating results in the second quarter of 2023, however, were
modestly ahead of internal expectations due, in part, to a strong response to a local sales promotion offered in mainland China," said Doug Hekking, Chief Financial Officer.
"Although the first half of this year benefitted from certain discrete sales activity not expected to recur in the back half of the year, our year-to-date results coupled with planned initiatives for the remainder of the year provide us
confidence to raise the bottom-end of our full year guidance. We will continue investing in strategies designed to deliver sustainable long-term growth while managing costs in line with forecasted sales levels."
Balance Sheet and Share Repurchase Activity
The Company generated $10 million of operating cash flow during the second quarter and ended the quarter with $300 million in cash and cash equivalents while remaining debt-free. The Company did not repurchase shares during the quarter and, as
of July 1, 2023, had approximately $83 million remaining under the current share repurchase authorization.
Management Commentary Document and Conference Call
For further information on the USANA's operating results, please see the Management Commentary document, which has been posted on the Company's website (http://ir.usana.com) under the Investor Relations section. USANA's management team will
hold a conference call and webcast to discuss today's announcement with investors on Wednesday, July 26, 2023 at 11:00 AM Eastern Time. Investors may listen to the call by accessing USANA's website at http://ir.usana.com. The call
will consist of brief opening remarks by the Company's management team, followed by a questions and answers session.
Non-GAAP Financial Measures
The Company prepares its financial statements using U.S. generally accepted accounting principles ("U.S. GAAP" or "GAAP"). Constant currency net sales, earnings, EPS and other currency-related financial information (collectively, "Financial
Results") are non-GAAP financial measures that remove the impact of fluctuations in foreign-currency exchange rates ("FX") and help facilitate period-to-period comparisons of the Company's Financial Results that we believe provide investors an
additional perspective on trends and underlying business results. Constant currency Financial Results are calculated by translating the current period's Financial Results at the same average exchange rates in effect during the applicable
prior-year period and then comparing this amount to the prior-year period's Financial Results.
USANA develops and manufactures high-quality nutritional supplements, functional foods and personal care products that are sold directly to Associates and Preferred Customers throughout the United States, Canada, Australia, New Zealand, Hong
Kong, China, Japan, Taiwan, South Korea, Singapore, Mexico, Malaysia, the Philippines, the Netherlands, the United Kingdom, Thailand, France, Belgium, Colombia, Indonesia, Germany, Spain, Romania, and Italy. More information on USANA can be found
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these
forward-looking statements, which involve a number of risks and uncertainties, including: uncertainty related to the COVID-19 pandemic ("COVID-19") to our business, operations and financial results; the potential for a resurgence of COVID-19
spread in any of our markets in the future; the impact of COVID-19 on the domestic and world economies, including any negative impact on discretionary spending, consumer demand, and consumer behavior in general; regulatory risk in China in
connection with the health products and direct selling business models; regulatory risk in the United States in connection with the direct selling business model; potential negative effects of deteriorating foreign and/or trade relations between
the United States and China; compliance with data privacy and security laws and regulations in our markets around the world; potential negative effects from geopolitical relations and conflicts, including the Russia-Ukraine conflict; potential
negative effects of material breaches of our information technology systems to the extent we experience a material breach; material failures of our information technology systems; global economic conditions generally, including increasing
inflationary pressure around the world and any negative impact on our operating costs, consumer demand and consumer behavior in general; reliance upon our network of independent Associates; risk associated with governmental regulation of our
products, manufacturing and direct selling business model; adverse publicity risks globally; risks associated with our international expansion and operations; and uncertainty relating to the fluctuation in U.S. and other international currencies.
The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission. The forward-looking statements
in this press release set forth our beliefs as of the date hereof. We do not undertake any obligation to update any forward-looking statement after the date hereof or to conform such statements to actual results or changes in the Company's
expectations, except as required by law.
| USANA Health Sciences, Inc. | |||||||||||||
| Consolidated Statements of Operations | |||||||||||||
| (In thousands, except per share data) | |||||||||||||
| (Unaudited) | |||||||||||||
| Quarter Ended | Six Months Ended | ||||||||||||
| 1-Jul-23 | 2-Jul-22 | 1-Jul-23 | 2-Jul-22 | ||||||||||
| Net sales | $ | 238,202 | $ | 264,474 | $ | 486,562 | $ | 537,341 | |||||
| Cost of sales | 43,326 | 49,517 | 91,845 | 100,900 | |||||||||
| Gross profit | 194,876 | 214,957 | 394,717 | 436,441 | |||||||||
| Operating expenses: | |||||||||||||
| Associate incentives | 102,380 | 119,204 | 208,450 | 238,824 | |||||||||
| Selling, general and administrative | 68,096 | 66,387 | 135,022 | 135,184 | |||||||||
| Earnings from operations | 24,400 | 29,366 | 51,245 | 62,433 | |||||||||
| Other income (expense), net | 2,410 | (58 | ) | 4,066 | 162 | ||||||||
| Earnings before income taxes | 26,810 | 29,308 | 55,311 | 62,595 | |||||||||
| Income taxes | 9,518 | 10,151 | 19,636 | 20,969 | |||||||||
| NET EARNINGS | $ | 17,292 | $ | 19,157 | $ | 35,675 | $ | 41,626 | |||||
| Earnings per share - diluted | $ | 0.89 | $ | 1.00 | $ | 1.84 | $ | 2.15 | |||||
| Weighted average shares outstanding - diluted | 19,427 | 19,244 | 19,377 | 19,362 |
| USANA Health Sciences, Inc. | ||||||
| Consolidated Balance Sheets | ||||||
| (In thousands) | ||||||
| (Unaudited) | ||||||
| As of | As of | |||||
| 1-Jul-23 | 31-Dec-22 | |||||
| ASSETS | ||||||
| Current Assets | ||||||
| Cash and cash equivalents | $ | 300,183 | $ | 288,420 | ||
| Inventories | 61,962 | 67,089 | ||||
| Prepaid expenses and other current assets | 25,501 | 28,873 | ||||
| Total current assets | 387,646 | 384,382 | ||||
| Property and equipment, net | 95,736 | 97,773 | ||||
| Goodwill | 16,859 | 17,368 | ||||
| Intangible assets, net | 29,997 | 32,432 | ||||
| Deferred tax assets | 15,914 | 9,799 | ||||
| Other assets* | 56,528 | 54,795 | ||||
| Total assets | $ | 602,680 | $ | 596,549 | ||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||
| Current Liabilities | ||||||
| Accounts payable | $ | 9,273 | $ | 11,049 | ||
| Other current liabilities | 104,566 | 132,784 | ||||
| Total current liabilities | 113,839 | 143,833 | ||||
| Deferred tax liabilities | 4,796 | 4,071 | ||||
| Other long-term liabilities | 15,221 | 14,173 | ||||
| Stockholders' equity | 468,824 | 434,472 | ||||
| Total liabilities and stockholders' equity | $ | 602,680 | $ | 596,549 | ||
| *Includes noncurrent inventories of $4,390 and $3,479 as of 1-Jul-23 and 31-Dec-22, respectively. Total inventories were $66,352 and $70,568 as of 1-Jul-23 and 31-Dec-22, respectively. |
| USANA Health Sciences, Inc. | ||||||||||||||||||||||||||
| Sales by Region | ||||||||||||||||||||||||||
| (In thousands) | ||||||||||||||||||||||||||
| (Unaudited) | ||||||||||||||||||||||||||
| Quarter Ended | ||||||||||||||||||||||||||
| July 1, 2023 | July 2, 2022 | Change from prior year | Currency impact on sales | % change excluding currency impact | ||||||||||||||||||||||
| Asia Pacific | ||||||||||||||||||||||||||
| Greater China | $ | 128,749 | 54.1 | % | $ | 140,775 | 53.2 | % | $ | (12,026 | ) | (8.5 | %) | $ | (6,948 | ) | (3.6 | %) | ||||||||
| Southeast Asia Pacific | 39,337 | 16.5 | % | 47,830 | 18.1 | % | (8,493 | ) | (17.8 | %) | (1,573 | ) | (14.5 | %) | ||||||||||||
| North Asia | 25,529 | 10.7 | % | 28,803 | 10.9 | % | (3,274 | ) | (11.4 | %) | (1,140 | ) | (7.4 | %) | ||||||||||||
| Asia Pacific Total | 193,615 | 81.3 | % | 217,408 | 82.2 | % | (23,793 | ) | (10.9 | %) | (9,661 | ) | (6.5 | %) | ||||||||||||
| Americas and Europe | 44,587 | 18.7 | % | 47,066 | 17.8 | % | (2,479 | ) | (5.3 | %) | 94 | (5.5 | %) | |||||||||||||
| $ | 238,202 | 100.0 | % | $ | 264,474 | 100.0 | % | $ | (26,272 | ) | (9.9 | %) | $ | (9,567 | ) | (6.3 | %) |
| Active Associates by Region (1) | ||||||||
| (Unaudited) | ||||||||
| As of | ||||||||
| July 1, 2023 | July 2, 2022 | |||||||
| Asia Pacific | ||||||||
| Greater China | 71,000 | 34.1% | 77,000 | 32.9% | ||||
| Southeast Asia Pacific | 57,000 | 27.4% | 69,000 | 29.5% | ||||
| North Asia | 33,000 | 15.9% | 36,000 | 15.4% | ||||
| Asia Pacific Total | 161,000 | 77.4% | 182,000 | 77.8% | ||||
| Americas and Europe | 47,000 | 22.6% | 52,000 | 22.2% | ||||
| 208,000 | 100.0% | 234,000 | 100.0% |
| Active Preferred Customers by Region (2) | ||||||||
| (Unaudited) | ||||||||
| As of | ||||||||
| July 1, 2023 | July 2, 2022 | |||||||
| Asia Pacific | ||||||||
| Greater China | 180,000 | 64.5% | 201,000 | 61.8% | ||||
| Southeast Asia Pacific | 25,000 | 9.0% | 34,000 | 10.5% | ||||
| North Asia | 18,000 | 6.4% | 21,000 | 6.5% | ||||
| Asia Pacific Total | 223,000 | 79.9% | 256,000 | 78.8% | ||||
| Americas and Europe | 56,000 | 20.1% | 69,000 | 21.2% | ||||
| 279,000 | 100.0% | 325,000 | 100.0% |
| (1) | Associates are independent distributors of our products who also purchase our products for their personal use. We only count as active | ||||||||
| those Associates who have purchased from us any time during the most recent three-month period, either for personal use or resale. | |||||||||
| (2) | Preferred Customers purchase our products strictly for their personal use and are not permitted to resell or to distribute the products. We | ||||||||
| only count as active those Preferred Customers who have purchased from us any time during the most recent three-month period. China | |||||||||
| utilizes a Preferred Customer program that has been implemented specifically for that market. |